Exposure to chlorpyrifos increases neutral lipid accumulation with accompanying increased de novo lipogenesis and decreased triglyceride secretion in McArdle-RH7777 hepatoma cells

Toxicology in Vitro

Volumn 32, Issue , 2016, Pages 181-189

  Howell, George Eli ^a   Mulligan, Charlee ^a   Young, Darian ^a   Kondakala, Sandeep ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Chlorpyrifos; De novo lipogenesis; Fatty acid oxidation; Fatty acid uptake; Hepatic steatosis; Triglyceride

Indexed keywords

CHLORPYRIFOS; FATTY ACID SYNTHASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; FATTY ACID; INSECTICIDE;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; HEPATOMA CELL; IN VITRO STUDY; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN SECRETION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DETERMINATION; RAT; ANIMAL; DRUG EFFECTS; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHLORPYRIFOS; FATTY ACIDS; INSECTICIDES; LIPID METABOLISM; LIPOGENESIS; LIVER NEOPLASMS; RATS; TRIGLYCERIDES;

EID: 84954326129     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2016.01.002     Document Type: Article

References (45)

1. Abdou H.M., ElMazoudy R.H. Oxidative damage, hyperlipidemia and histological alterations of cardiac and skeletal muscles induced by different doses of diazinon in female rats. J. Hazard. Mater. 2010, 182:273-278.
2. Abumrad N., Harmon C., Ibrahimi A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. J. Lipid Res. 1998, 39:2309-2318.
3. Acker C.I., Nogueira C.W. Chlorpyrifos acute exposure induces hyperglycemia and hyperlipidemia in rats. Chemosphere 2012, 89:602-608.
4. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., Poniachik J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond.) 2004, 106:635-643.
5. Berk P.D., Stump D.D. Mechanisms of cellular uptake of long chain free fatty acids. Mol. Cell. Biochem. 1999, 192:17-31.
6. Boren J., Rustaeus S., Olofsson S.O. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J. Biol. Chem. 1994, 269:25879-25888.
7. Caviglia J.M., Gayet C., Ota T., Hernandez-Ono A., Conlon D.M., Jiang H., Fisher E.A., Ginsberg H.N. Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J. Lipid Res. 2011, 52:1636-1651.
8. Chamberlain J.M., O'Dell C., Sparks C.E., Sparks J.D. Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting. Biochem. Biophys. Res. Commun. 2013, 430:66-71.
9. Choi S.H., Ginsberg H.N. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol. Metab. 2011, 22:353-363.
10. Crow J.A., Bittles V., Herring K.L., Borazjani A., Potter P.M., Ross M.K. Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos Oxon, paraoxon and methyl paraoxon. Toxicol. Appl. Pharmacol. 2012, 258:145-150.
11. DeBose-Boyd R.A., Ou J., Goldstein J.L., Brown M.S. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1477-1482.
12. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
13. Eddleston M., Eyer P., Worek F., Mohamed F., Senarathna L., von Meyer L., Juszczak E., Hittarage A., Azhar S., Dissanayake W., Sheriff M.H., Szinicz L., Dawson A.H., Buckley N.A. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet 2005, 366:1452-1459.
14. Eyer F., Roberts D.M., Buckley N.A., Eddleston M., Thiermann H., Worek F., Eyer P. Extreme variability in the formation of chlorpyrifos Oxon (CPO) in patients poisoned by chlorpyrifos (CPF). Biochem. Pharmacol. 2009, 78:531-537.
15. Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12(Suppl. 2):83-92.
16. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
17. Gilham D., Ho S., Rasouli M., Martres P., Vance D.E., Lehner R. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB J. 2003, 17:1685-1687.
18. Gomez-Lechon M.J., Donato M.T., Martinez-Romero A., Jimenez N., Castell J.V., O'Connor J.E. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 2007, 165:106-116.
19. Grube A., Donaldson D., Kiely T., Wu L. Pesticides Industry Sales and Usage: 2006 and 2007 Market Estimates. Agency, U.S.E.P. 2011.
20. Hansson P.K., Asztely A.K., Clapham J.C., Schreyer S.A. Glucose and fatty acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availability. Biochim. Biophys. Acta 2004, 1684:54-62.
21. He W., Guo W., Qian Y., Zhang S., Ren D., Liu S. Synergistic hepatotoxicity by cadmium and chlorpyrifos: disordered hepatic lipid homeostasis. Mol. Med. Rep. 2015, 12:303-308.
22. Howell G., Mangum L. Exposure to bioaccumulative organochlorine compounds alters adipogenesis, fatty acid uptake, and adipokine production in NIH3T3-L1 cells. Toxicol. in Vitro 2011, 25:394-402.
23. Howell G., Deng X., Yellaturu C., Park E.A., Wilcox H.G., Raghow R., Elam M.B. N-3 polyunsaturated fatty acids suppress insulin-induced SREBP-1c transcription via reduced trans-activating capacity of LXRalpha. Biochim. Biophys. Acta 2009, 1791:1190-1196.
24. Ko K.W., Erickson B., Lehner R. Es-x/Ces1 prevents triacylglycerol accumulation in McArdle-RH7777 hepatocytes. Biochim. Biophys. Acta 2009, 1791:1133-1143.
25. Kwekel J.C., Desai V.G., Moland C.L., Branham W.S., Fuscoe J.C. Age and sex dependent changes in liver gene expression during the life cycle of the rat. BMC Genomics 2010, 11:675.
26. Lasram M.M., Annabi A.B., El Elj N., Selmi S., Kamoun A., El-Fazaa S., Gharbi N. Metabolic disorders of acute exposure to malathion in adult Wistar rats. J. Hazard. Mater. 2009, 163:1052-1055.
27. Lasram M.M., Dhouib I.B., Bouzid K., Lamine A.J., Annabi A., Belhadjhmida N., Ahmed M.B., Fazaa S.E., Abdelmoula J., Gharbi N. Association of inflammatory response and oxidative injury in the pathogenesis of liver steatosis and insulin resistance following subchronic exposure to malathion in rats. Environ. Toxicol. Pharmacol. 2014, 38:542-553.
28. Lassiter T.L., Brimijoin S. Rats gain excess weight after developmental exposure to the organophosphorothionate pesticide, chlorpyrifos. Neurotoxicol. Teratol. 2008, 30:125-130.
29. Lassiter T.L., Ryde I.T., Mackillop E.A., Brown K.K., Levin E.D., Seidler F.J., Slotkin T.A. Exposure of neonatal rats to parathion elicits sex-selective reprogramming of metabolism and alters the response to a high-fat diet in adulthood. Environ. Health Perspect. 2008, 116:1456-1462.
30. Lehner R., Vance D.E. Cloning and expression of a cDNA encoding a hepatic microsomal lipase that mobilizes stored triacylglycerol. Biochem. J. 1999, 343(Pt 1):1-10.
31. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
32. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., Forlani G., Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107:450-455.
33. Moon B.C., Hernandez-Ono A., Stiles B., Wu H., Ginsberg H.N. Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler. Thromb. Vasc. Biol. 2012, 32:236-246.
34. Poulin P., Krishnan K. An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. J. Toxicol. Environ. Health 1995, 46:117-129.
35. Quiroga A.D., Li L., Trotzmuller M., Nelson R., Proctor S.D., Kofeler H., Lehner R. Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia. Hepatology 2012, 56:2188-2198.
36. Raspotnig G., Fauler G., Jantscher A., Windischhofer W., Schachl K., Leis H.J. Colorimetric determination of cell numbers by Janus green staining. Anal. Biochem. 1999, 275:74-83.
37. Ross M.K., Streit T.M., Herring K.L. Carboxylesterases: dual roles in lipid and pesticide metabolism. J. Pestic. Sci. 2010, 35:257-264.
38. Rouimi P., Zucchini-Pascal N., Dupont G., Razpotnik A., Fouche E., De Sousa G., Rahmani R. Impacts of low doses of pesticide mixtures on liver cell defence systems. Toxicol. in Vitro 2012, 26:718-726.
39. Shimomura I., Shimano H., Horton J.D., Goldstein J.L., Brown M.S. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J. Clin. Invest. 1997, 99:838-845.
40. Slotkin T.A., Brown K.K., Seidler F.J. Developmental exposure of rats to chlorpyrifos elicits sex-selective hyperlipidemia and hyperinsulinemia in adulthood. Environ. Health Perspect. 2005, 113:1291-1294.
41. Timchalk C., Nolan R.J., Mendrala A.L., Dittenber D.A., Brzak K.A., Mattsson J.L. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 2002, 66:34-53.
42. Utzschneider K.M., Kahn S.E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006, 91:4753-4761.
43. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol. 2009, 76:215-228.
44. Wei E., Ben Ali Y., Lyon J., Wang H., Nelson R., Dolinsky V.W., Dyck J.R., Mitchell G., Korbutt G.S., Lehner R. Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure. Cell Metab. 2010, 11:183-193.
45. Wilson P.W., Kannel W.B., Silbershatz H., D'Agostino R.B. Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 1999, 159:1104-1109.